Literature DB >> 6109715

Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.

C Ezrin-Waters, M V Seeman, P Seeman.   

Abstract

All the patients (N = 94) of an outpatient clinic for schizophrenia were evaluated for the presence and severity of neuroleptic induced tardive dyskinesia. Fourty-four percent of the patients showed some degree of tardive dyskinesia. The proportion of patients with tardive dyskinesia increased directly with age and with number of years of neuroleptic treatment. Recent dose reduction exacerbated the syndrome. There were no gender differences in the clinic as a whole. Severity of dyskinesia correlated with anticholinergic drug use, with the piperazine/butyrophenone group of neuroleptics and with the use of depot-administered drugs. The depot correlation was highly significant in the under-30 age group.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6109715

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

1.  The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies.

Authors:  H Morgenstern; W M Glazer; D Niedzwiecki; P Nourjah
Journal:  Am J Public Health       Date:  1987-06       Impact factor: 9.308

2.  Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response.

Authors:  Rosalinda C Roberts; Joy K Roche; Robert R Conley; Adrienne C Lahti
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

3.  Fluphenazine-induced acute and tardive dyskinesias in monkeys.

Authors:  B Kovacic; E F Domino
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 4.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.